Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells

被引：4

作者：

Sakai, Osamu ^{[1
]}

Ogino, Shoji ^{[2
]}

Tsukui, Toshihiro ^{[2
]}

Igase, Masaya ^{[1
]}

Mizuno, Takuya ^{[1
]}

机构：

[1] Yamaguchi Univ, Joint Grad Sch Vet Med, Lab Mol Diagnost & Therapeut, 1677-1 Yoshida, Yamaguchi 7538515, Japan

[2] Nippon Zenyaku Kogyo Co Ltd, Koriyama, Fukushima 9630196, Japan

来源：

JOURNAL OF VETERINARY MEDICAL SCIENCE | 2021年 / 83卷 / 10期

关键词：

adoptive immunotherapy; canine; CD20; chimeric antigen receptorT cell; monoclonal antibody; RITUXIMAB; LYMPHOMA; THERAPY; MODEL; DOGS;

D O I：

10.1292/jvms.21-0326

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

Chimeric antigen receptor (CAR) CAR-T cell therapy targeting CD20 can be a novel adoptive cell therapy for canine patients with B-cell malignancy. After injection of the CAR-T cells in vivo, monitoring circulating CAR-T cells is essential to prove in vivo persistence of CAR-T cells. In this study, we developed a novel monoclonal antibody against canine CD20 CAR, whose single-chain variable fragment was derived from the our previously reported anti-canine CD20 therapeutic antibody. Furthermore, we proved that this monoclonal antibody can detect therapeutic anti-canine CD20 chimeric antibody in the serum from healthy beagle dogs injected with the therapeutic antibody for safety study. This monoclonal antibody is a useful tool for monitoring both canine CD20-CAR-T cells and anti-canine CD20 therapeutic antibody for canine lymphoma.

引用

页码：1495 / 1499

页数：5

共 50 条

[41] Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma [J].

Lorenc, Rachel ;

Shouval, Roni ;

Flynn, Jessica R. ;

Devlin, Sean M. ;

Saldia, Amethyst ;

De Abia, Alejandro Luna ;

De Lapuerta, Magdalena Corona ;

Tomas, Ana Alarcon ;

Cassanello, Giulio ;

Leslie, Lori A. ;

Rejeski, Kai ;

Lin, Richard J. ;

Scordo, Michael ;

Shah, Gunjan L. ;

Palomba, M. Lia ;

Salles, Gilles ;

Park, Jae ;

Giralt, Sergio A. ;

Perales, Miguel-Angel ;

Ip, Andrew ;

Dahi, Parastoo B. .

TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (10) :990-1000

[42] Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression [J].

Curran, Kevin J. ;

Seinstra, Beatrijs A. ;

Nikhamin, Yan ;

Yeh, Raymond ;

Usachenko, Yelena ;

van Leeuwen, Dayenne G. ;

Purdon, Terence ;

Pegram, Hollie J. ;

Brentjens, Renier J. .

MOLECULAR THERAPY, 2015, 23 (04) :769-778

[43] Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells [J].

Evans, Andrew G. ;

Rothberg, Paul G. ;

Burack, W. Richard ;

Huntington, Scott F. ;

Porter, David L. ;

Friedberg, Jonathan W. ;

Liesveld, Jane L. .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (02) :205-209

[44] Enhancing CD19 Chimeric Antigen Receptor T Cells Through Memory-Enriched T Cells [J].

El Marabti, Ettaib ;

Abdel-Wahab, Omar .

CLINICAL CANCER RESEARCH, 2023, 29 (04) :694-696

[45] Potassium/sodium cation carriers robustly upregulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells [J].

Torun, Anna ;

Zdanowicz, Aleksandra ;

Miazek-Zapala, Nina ;

Zapala, Piotr ;

Pradhan, Bhaskar ;

Jedrzejczyk, Marta ;

Ciechanowicz, Andrzej ;

Pilch, Zofia ;

Skorzynski, Marcin ;

Slabicki, Mikolaj ;

Rymkiewicz, Grzegorz ;

Barankiewicz, Joanna ;

Martines, Claudio ;

Laurenti, Luca ;

Struga, Marta ;

Winiarska, Magdalena ;

Golab, Jakub ;

Kucia, Magdalena ;

Ratajczak, Mariusz Z. ;

Huczynski, Adam ;

Calado, Dinis P. ;

Efremov, Dimitar G. ;

Zerrouqi, Abdessamad ;

Pyrzynska, Beata .

HAEMATOLOGICA, 2025, 110 (07) :1555-1572

[46] Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells [J].

An, Na ;

Hou, Yun Nan ;

Zhang, Qiao Xia ;

Li, Ting ;

Zhang, Qiong Li ;

Fang, Cheng ;

Chen, Huan ;

Lee, Hon Cheung ;

Zhao, Yong Juan ;

Du, Xin .

MOLECULAR PHARMACEUTICS, 2018, 15 (10) :4577-4588

[47] Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma [J].

Panjwani, M. Kazim ;

Smith, Jenessa B. ;

Schutsky, Keith ;

Gnanandarajah, Josephine ;

O'Connor, Colleen M. ;

Powell, Daniel J., Jr. ;

Mason, Nicola J. .

MOLECULAR THERAPY, 2016, 24 (09) :1602-1614

[48] Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia [J].

Danylesko, Ivetta ;

Chowers, Guy ;

Shouval, Roni ;

Besser, Michal J. ;

Jacoby, Elad ;

Shimoni, Avichai ;

Nagler, Arnon ;

Avigdor, Abraham .

CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2020, 68 (01) :17-22

[49] The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies [J].

Markovic, Tijana ;

Podgornik, Helena ;

Avsec, Damjan ;

Nabergoj, Sanja ;

Mlinaric-Rascan, Irena .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)

[50] Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor [J].

Singh, H. ;

Moyes, J. S. E. ;

Huls, M. H. ;

Cooper, L. J. N. .

CANCER GENE THERAPY, 2015, 22 (02) :95-100

← 1 2 3 4 5 →